Clinical Trials Directory

Trials / Unknown

UnknownNCT02646137

Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma

Comparison of Single Session Transarterial Chemoembolization Combined With Microwave Ablation or Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Sherief Abd-Elsalam · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for patients with surgically unresectable hepatocellular carcinoma.

Detailed description

To compare between combination treatment with radiofrequency or microwave ablation followed by transarterial chemoembolization and performed in a single session.

Conditions

Interventions

TypeNameDescription
DRUGTransarterial chemoembolization (TACE)TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
PROCEDURERadiofrequency ablation combined with TACERadiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
PROCEDUREMicrowave ablation combined with TACEMicrowave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis

Timeline

Start date
2015-01-01
Primary completion
2023-12-01
Completion
2023-12-01
First posted
2016-01-05
Last updated
2018-01-09

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT02646137. Inclusion in this directory is not an endorsement.